AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25567214
Drug: Gabapentin 500
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 500 mg + Zolpidem 10 mg
Trial: 18246854
Drug: Ericksonian therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ericksonian therapy using hypnosis (ET)
Trial: 23174499
Drug: Brief dynamic
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief dynamic therapy (BDT)
Trial: 12884985
Drug: 4-chloro-m-cresol 75
RxNorm normalized name: p-Chloro-m-cresol
DrugBank: Chlorocresol (DB16864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-chloro-m-cresol 75 micromol L(‐1)
Trial: 9231315
Drug: Methylphenidate (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (0.3 and 0.5/0.6 mg/kg daily for a minimum of 1 week)
Trial: 30694338
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy plus bid S. boulardii 250 mg
Trial: 30694338
Drug: Standard sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard sequential therapy of bid omeprazole 20 mg plus amoxicillin 1 g for 5 days, followed by bid omeprazole 20 mg, clarithromycin 500 mg and metronidazole 500 mg
Trial: 17879541
Drug: SQFZI combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQFZI combined with chemotherapy (docetaxel, flurouracil, calcium folinate)
Trial: 17879541
Drug: SQFZI combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQFZI combined with chemotherapy
Trial: 17457123
Drug: Microemulsion propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microemulsion propofol (Aquafol; 2 mg/kg bolus followed by variable rate infusion for 60 min)
Trial: 17457123
Drug: Lipid emulsion
RxNorm normalized name: propofol lipid emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid emulsion propofol (Diprivan; 2 mg/kg bolus followed by variable rate infusion for 60 min)
Trial: 10789325
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (n = 36) underwent four, monthly 25% drug reduction stages
Trial: 10789325
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n = 20) with no planned drug changes
Trial: 10789325
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (n = 36) undergoing drug reduction
Trial: 9149200
Drug: ANP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ANP infusion (2, 4, and 6 pmol/kg.min for 15 min each)
Trial: 31161361
Drug: Local desmopressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local desmopressin (10 μg) administered as a single puff in each side of the nasal cavity 30 minutes before surgery
Trial: 26979520
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg twice daily in combination with dipyridamole slow-release 200 mg twice daily
Trial: 26979520
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg twice daily alone
Trial: 19960983
Drug: Renshen Jianxin
RxNorm normalized name: Dianexin
DrugBank: Dianexin (DB15000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renshen Jianxin Capsule (RJC)
Trial: 11135086
Drug: L-folinic acid
RxNorm normalized name: L-Folinic acid
DrugBank: Levoleucovorin (DB11596)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-folinic acid (FNA) 20 mg/day
Trial: 11135086
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (FA) 15 mg/day
Trial: 9853274
Drug: valsartan 80
RxNorm normalized name: valsartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valsartan 80 mg o.d.
Trial: 9853274
Drug: valsartan 80
RxNorm normalized name: valsartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valsartan 80 mg o.d. + indomethacin 50 mg bid
Trial: 9853274
Drug: enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril 20 mg o.d. + indomethacin 50 mg bid
Trial: 8037389
Drug: Prochlorperazine 25
RxNorm normalized name: prochlorperazine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prochlorperazine 25 mg rectal suppository
Trial: 31852749
Drug: 2×10^6/kg BM-MNC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2×10^6/kg BM-MNC injection
Trial: 31852749
Drug: 5×10^6/kg BM-MNC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5×10^6/kg BM-MNC injection
Trial: 25408331
Drug: Serelaxin 10
RxNorm normalized name: serelaxin
DrugBank: Serelaxin (DB05794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serelaxin 10 µg/kg/day
Trial: 25408331
Drug: Serelaxin 30
RxNorm normalized name: serelaxin
DrugBank: Serelaxin (DB05794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serelaxin 30 µg/kg/day
Trial: 25408331
Drug: Serelaxin 100
RxNorm normalized name: serelaxin
DrugBank: Serelaxin (DB05794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serelaxin 100 µg/kg/day
Trial: 25408331
Drug: Serelaxin 30
RxNorm normalized name: serelaxin
DrugBank: Serelaxin (DB05794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serelaxin 30 µg/kg/day (Caucasian cohort)
Trial: 23278466
Drug: Vasoconstrictor (somatostatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasoconstrictor (somatostatin or terlipressin infusion)
Trial: 23278466
Drug: Proton Pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton Pump Inhibitor (omeprazole or pantoprazole infusion)
Trial: 20541832
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily training plus usual care
Trial: 19471252
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) maintenance therapy
Trial: 17461851
Drug: TMC114/ritonavir (TMC114/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC114/ritonavir (TMC114/r) 600/100 mg twice a day
Trial: 17461851
Drug: Control protease
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control protease inhibitor (CPI)
Trial: 15141519
Drug: Intrapartum antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapartum antibiotic prophylaxis with Penicillin G or Clindamycin for GBS carriers (161 out of 754 newborns, 21.4%)
Trial: 1440744
Drug: Intensive intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive intervention (18 therapy appointments over one year, including one home visit)
Trial: 3770386
Drug: Viscous lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viscous lidocaine gargle (2%) diluted with tap water (39 ml + 15 ml)
Trial: 3770386
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (neither viscous lidocaine nor placebo)
Trial: 30337746
Drug: Group D1
RxNorm normalized name: PHOSPHOLIPASE D1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D1 (10 mL of 0.375% ropivacaine + dexmedetomidine 0.2 μg/(kg×h))
Trial: 30337746
Drug: Group D2
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group D2 (10 mL of 0.375% ropivacaine + dexmedetomidine 0.7 μg/(kg×h))
Trial: 30337746
Drug: Group R
RxNorm normalized name: Typhus group rickettsia Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group R (10 mL of 0.375% ropivacaine)
Trial: 15781679
Drug: UV facial
RxNorm normalized name: ZINC OXIDE 70 g in 1000 g / OCTINOXATE 75 g in 1000 g TOPICAL LOTION [EltaMD UV Facial SPF30 Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UV facial photograph and photoaging information plus sunless tanning lotion
Trial: 10505829
Drug: Masked review
RxNorm normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Masked review of a complete pediatric ophthalmic exam
Trial: 28864226
Drug: CDDP with
RxNorm normalized name: CDDP
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CDDP with Mg (2.5mg/kg CDDP, 40mg/kg MgSO4)
Trial: 28864226
Drug: CDDP with
RxNorm normalized name: CDDP
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CDDP with Mg
Trial: 23314670
Drug: Bifidobacterium infantis
RxNorm normalized name: Bifidobacterium infantis
DrugBank: Bifidobacterium longum infantis (DB14222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium infantis natren life start strain super strain (Lifestart 2) (2×10(9) colony‐forming units per capsule) for 3 weeks
Trial: 19947443
Drug: Strontium ranelate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strontium ranelate, a first-line agent for the treatment of postmenopausal osteoporosis.
Trial: 17123867
Drug: Melatonin (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (intravenous administration)
Trial: 15170026
Drug: Salmeterol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (50 microg twice a day)
Trial: 9433336
Drug: Paroxetine 10
RxNorm normalized name: PARoxetine 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 10 mg/day
Trial: 7663801
Drug: L-NMMA (490
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (490 mg by inhalation)
Trial: 7663801
Drug: Prednisolone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (30 mg orally for 3 days)
Trial: 2698244
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg pindolol
Trial: 2698244
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg propranolol
Trial: 30451047
Drug: Self-administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administration
Trial: 27576596
Drug: Buprenorphine mixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine mixed with lignocaine 2% with adrenaline 1:80,000 (0.01mg buprenorphine/ml)
Trial: 23153715
Drug: Progressive muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive muscle relaxation as an add-on therapy for refractory epilepsy
Trial: 17103437
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) therapy (1 mg/m²/day) for 2 years
Trial: 17103437
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) therapy (1.5 mg/m²/day) for 1 year after 1 year of observation
Trial: 17103437
Drug: Observation without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Observation without GH treatment for 1 year
Trial: 3777545
Drug: Anticoagulant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant treatment (heparin for 21 days followed by antivitamin K drugs for 30 days)
Trial: 3777545
Drug: Acute hemodilution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute hemodilution with 40,000 daltons molecular weight dextran, haematocrit 0.25-0.30, followed by the same anticoagulant treatment as in group I
Trial: 9643595
Drug: No alteration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No alteration of anticoagulant treatment (study group)
Trial: 9643595
Drug: Warfarin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin treatment stopped for 2-3 days (control group)
Trial: 27890713
Drug: Single IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV infusion of 20, 100, or 200 × 10^6 human bone marrow-derived mesenchymal stem cells
Trial: 27890713
Drug: Single IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV infusion of human mesenchymal stem cells
Trial: 21311063
Drug: High-sensitivity C-reactive
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sensitivity C-reactive protein >3 mg/L
Trial: 21311063
Drug: Homocysteine >15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homocysteine >15 umol/L
Trial: 17418554
Drug: Budesonide 200
RxNorm normalized name: budesonide 200 mcg/inh inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 200 microg twice daily + Montelukast 5mg once daily
Trial: 17418554
Drug: Budesonide 200
RxNorm normalized name: budesonide 200 mcg/inh inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 200 microg twice daily + Formoterol 9 microg twice daily
Trial: 17418554
Drug: Budesonide 200
RxNorm normalized name: budesonide 200 mcg/inh inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 200 microg twice daily + Montelukast 5mg once daily (second month)
Trial: 17418554
Drug: Budesonide 200
RxNorm normalized name: budesonide 200 mcg/inh inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 200 microg twice daily + Formoterol 9 microg twice daily (second month)
Trial: 17418554
Drug: Budesonide 400
RxNorm normalized name: Budesonide 400 microgram/actuation powder for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 400 microg twice daily (first and second month)
Trial: 15145911
Drug: Treatment to
RxNorm normalized name: Lice Treatment Topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment to below 140/90 mm Hg
Trial: 11304898
Drug: Methylprednisolone (MP)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (MP) 1 mg/kg loading infusion over 30 minutes followed by 1 mg/kg/day continuous i.v. infusion
Trial: 9789204
Drug: 0.006 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.006 mg/kg apomorphine
Trial: 9789204
Drug: 0.012 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.012 mg/kg apomorphine
Trial: 2657045
Drug: Oral ritodrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ritodrine (20 mg every four hours)
Trial: 2657045
Drug: Oral terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terbutaline (5 mg every four hours)
Trial: 29795365
Drug: Control (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (daily self‐weighing and text messaging feedback)
Trial: 19141661
Drug: Monthly home
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly home visits from trained volunteers over a 9‐month period
Trial: 16454834
Drug: Peg-interferon alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peg-interferon alpha-2b (100 microg/wk) + lamivudine (100 mg/day)
Trial: 15237079
Drug: Algorithm-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm-guided treatment (ALGO)
Trial: 10322844
Drug: Fuganlin (FGL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuganlin (FGL) oral liquid
Trial: 10322844
Drug: Antipyretic oral
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Antipyretic oral liquid (Control)
Trial: 6817658
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention (absence of inhaled cromoglycate)
Trial: 31702402
Drug: Clonazepam 2
RxNorm normalized name: clonazepam 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonazepam 2 mg test tablet (Sanofi‐Aventis de Colombia S.A.)
Trial: 26342812
Drug: Transurethral injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transurethral injection of polyacrylamide hydrogel (Bulkamid) in Group A (previous radiotherapy)
Trial: 26342812
Drug: Transurethral injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transurethral injection of polyacrylamide hydrogel (Bulkamid) in Group B (no previous radiotherapy)
Trial: 11250974
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg lefradafiban three times daily
Trial: 11250974
Drug: 45 mg
RxNorm normalized name: lutein 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg lefradafiban three times daily
Trial: 11250974
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg lefradafiban three times daily
Trial: 9827736
Drug: MDI-spacer (salbutamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI-spacer (salbutamol delivered via metered-dose inhaler plus spacer, 2.4 mg/h, 4 puffs at 10-minute intervals for 3 hours)
Trial: 9827736
Drug: NEB (nebulized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEB (nebulized salbutamol, 6 mg/h, 1.5 mg at 15-minute intervals for 3 hours)
Trial: 10150549
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition (TPN) with midazolam sedation
Trial: 26754759
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (CI) of beta-lactam antibiotics
Trial: 26754759
Drug: Intermittent bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bolus (IB) dosing of beta-lactam antibiotics
Trial: 26754759
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (CI) and Intermittent bolus (IB) dosing
Trial: 21913408
Drug: reamberin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: reamberin (800 ml/day for 8 days)
Trial: 10780124
Drug: Active Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active Nicotine Patch
Trial: 8398824
Drug: Serum thymidine
RxNorm normalized name: Thymidine
DrugBank: Thymidine (DB04485)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum thymidine kinase (STK) < 6 U/l
Trial: 8398824
Drug: Serum thymidine
RxNorm normalized name: Thymidine
DrugBank: Thymidine (DB04485)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum thymidine kinase (STK) > 11 U/l
Trial: 8398824
Drug: ABCM treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABCM treatment (adriamycin, BCNU, cyclophosphamide and melphalan)
Trial: 3095558
Drug: Central venous
RxNorm normalized name: ACCUGUIDE CENTRAL VENOUS CATHETER KIT C1409AK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Central venous parenteral nutrition (TPN)
Trial: 24032716
Drug: Traditional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional physical therapy exercise program
Trial: 21963124
Drug: Vacuum-assisted socket
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vacuum-assisted socket suspension system (VASS)
Trial: 21963124
Drug: Pin lock
RxNorm normalized name: pin oak pollen extract
DrugBank: Quercus palustris pollen (DB10887)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pin lock suspension system
Trial: 10764703
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for one week (H pylori eradication group)
Trial: 10764703
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg once daily for 12 months (H pylori positive group)
Trial: 10764703
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (H pylori negative control group)
Trial: 8834976
Drug: Pirenzepine 100
RxNorm normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine 100 mg at bedtime
Trial: 1349028
Drug: TRZ alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRZ alone (5.0 mg)
Trial: 1349028
Drug: TRZ+MCTZ-2.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRZ+MCTZ-2.5 mg
Trial: 1349028
Drug: TRZ+MCTZ-5.0 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRZ+MCTZ-5.0 mg
Trial: 6146258
Drug: Anticoagulants, platelet-active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulants, platelet-active drugs, lipid-lowering regimens, antiarrhythmic agents, physical exercise, calcium antagonists
Trial: 26982282
Drug: Cream (for
RxNorm normalized name: Cetaphil Moisturizing Body Cream (For Dry,Sensitive Skin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream (for infants with BPD)
Trial: 21105887
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg azithromycin for 3 days (U group)
Trial: 21105887
Drug: 4-week levofloxacin-azithromycin
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week levofloxacin-azithromycin combination (P group)
Trial: 21105887
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment with both azithromycin and 4-week levofloxacin-azithromycin (U+P group)
Trial: 18599162
Drug: Blended learning
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended learning program (including e-learning) administered to 26 new nurses